Monthly intravesical bacillus Calmette-Guérin maintenance therapy for non-muscle-invasive bladder cancer: 10-year experience in a single institute

Abstract

Intravesical bacillus Calmette-Guérin (BCG) therapy is the standard prophylaxis for recurrence of non-muscle-invasive bladder cancer (NMIBC). The aim of this study was to confirm the recurrence- and progression-preventing efficacy and safety of 12 times monthly BCG maintenance therapy for NMIBC. This study included 126 patients diagnosed with Ta, T1 and carcinoma in situ bladder cancer between January 2000 and December 2009. Thirty-four patients in the no maintenance group received a single 6-week course of intravesical immunotherapy after transurethral resection of the bladder tumor (TUR-BT). Ninety-two patients in the maintenance group received a 12-month course after a single 6-week course of intravesical immunotherapy. Recurrence, progression and side effects were assessed. End-points were recurrence-free survival (RFS), progression-free survival (PFS) and disease-specific survival (DSS). The estimated median RFS was 87 months (95% CI 53.0–120.9) in the maintenance group and 48 months (95% CI 0–96.8) in the no maintenance group (log-rank test; P=0.002). The 2-year cumulative RFS rates were 77.3% in the maintenance group and 52.6% in the no maintenance group. Median PFS and DSS were not estimable in both groups. The 2-year cumulative PFS rates were 91.1% in the maintenance group and 80.5% in the no maintenance group (log-rank test; P=0.178). The 2-year cumulative DSS rates were 97.7% in the maintenance group and 91.4% in the no maintenance group (log-rank test; P=0.111). The overall side effects were 40.2% in the maintenance group and 44.1% in the no maintenance group. Monthly maintenance immunotherapy appears to increase RFS rates in high-risk NMIBC. Further study is required to evaluate the efficacy of BCG monthly maintenence for increasing the PFS rate.

Introduction

In 2008, an estimated 386,300 new cases and 150,200 deaths from bladder cancer were reported. The majority of bladder cancer occurs in males and there is a 14-fold variation in incidence internationally (1). Non-muscle-invasive bladder cancer (NMIBC) accounts for approximately 80% of total bladder cancer cases (2). Intravesical bacillus Calmette-Guérin (BCG) therapy is the standard prophylaxis for recurrence of NMIBC (3). However, after a single 6-week course of intravesical immunotherapy after transurethral resection of bladder tumor (TUR-BT), the 5-year recurrence rates range from 16 to 59% (4–6).

A randomized Southwest Oncology Group (SWOG) study reported the results of intravesical maintenance immunotherapy. This revealed that the median recurrence-free survival (RFS) time was twice as long in the 3-week maintenance arm compared to the no maintenance arm, and patients had significantly longer worsening-free survival (4). At least 1 week following biopsy of carcinoma in situ (CIS) and resection of any stage Ta or T1 transitional cell carcinomas, patients were started on a 6-week induction course of intravesical and percutaneous Connaught BCG. Maintenance therapy of the SWOG study consisted of intravesical and percutaneous BCG each week for 3 weeks, administered 3, 6, 12, 18, 24, 30 and 36 months from the initiation of the induction therapy.

A number of randomized studies have focused on the benefit of maintenance therapy following initial BCG induction (7). Meta-analyses reported that BCG maintenance significantly reduces recurrence or progression in patients with NMIBC (8,9). Several studies, however, revealed no benefit of maintenance therapy in controlling tumor recurrence or progression (10–12). Differences in the results are possibly due to the maintenance schedules. The maintenance schedules varied considerably and it appears that a weekly, monthly, quarterly or 6-monthly schedule for 1–2 years may be immunologically suboptimal (4,10,11,13). The aim of this study was to confirm the recurrence- and progression-preventing efficacy and safety of 12 times monthly BCG maintenance therapy for NMIBC.

Materials and methods

This case-control study included 126 patients diagnosed with Ta, T1 and CIS bladder cancer between January 2000 and December 2009, who received intravesical immunotherapy. The inclusion criteria were high-risk NMIBC and recurrent NMIBC, such as, pathologically confirmed Ta, T1 and CIS of the bladder, administration of intravesical initiation or maintenance immunotherapy, performance status of 0–2, ability to undergo cystoscopy and TUR-BT, and intact function of main organs (14). Exclusion criteria included reduced dosage of BCG Tice strain, failure of consecutive treatment, strongly positive tuberculin test, history of intravesical BCG instillation, severe bladder irritation before the start of BCG administration and active serious medical complications. Of 126 patients with NMIBC, 34 patients in the no maintenance group received a single 6-week course of intravesical immunotherapy after TUR-BT. Ninety-two patients in the maintenance group received 12 times monthly maintenance therapy course after a single 6-week course of intravesical immunotherapy after TUR-BT.

Prior to intravesical immunotherapy, patients provided a health history and underwent a physical examination, urinalysis, urine cytology, complete blood count, blood urea nitrogen, serum creatinine, liver function test and chest X-ray. The single 6-week course of intravesical immunotherapy started within 1 week after TUR-BT with 12.5 mg of BCG Tice strain (OncoTICE; Oregano, West Orange, NJ, USA). BCG Tice strain was first suspended in 3 ml diluents, followed by dilution with 40 ml physiological saline. That suspension was then instilled into the bladder via a urethral catheter. Patients were required to hold their urine for ∼2 h after instillation (15). BCG treatment was repeated weekly for 6 consecutive weeks. An additional 12 times monthly course after the single 6-week course of intravesical immunotherapy was initiated 1 month later after a single 6-week course with BCG Tice strain. BCG treatment was repeated monthly for 12 consecutive months.

Efficacy of the treatment regimens was assessed on the basis of cystoscopy and urinary cytology finding. The patients were followed up every 3 months during the first 2 years, and every 6 months thereafter (14). End-points were RFS and progression-free survival (PFS). When tumor recurrence was suspected on the basis of the findings of cystoscopy and urinary cytology, confirmation was carried out by performing TUR-BT. Progression at the time of recurrence was defined as pathological stage T2 disease or greater, or the use of cystectomy, systemic chemotherapy or radiation therapy. Kaplan-Meier survival curves were used to estimate disease-free survival. P-value <0.05 was considered to denote statistical significance.

Results

The median follow-up period was 43 months (interquartile range 18–64; range 3–123) in the maintenance group and 16.5 months (interquartile range 6–35.75; range 3–75) in the no maintenance group. The baseline clinicopathological characteristics of the NMIBC patients are shown in Table I. One hundred and twenty-six patients were eligible for enrollment in our study. In total, 92 patients with Ta (n=25) and T1 (n=67) were treated with intravesical BCG maintenance therapy, and 34 patients with Ta (n=15) and T1 (n=19) were treated with intravesical BCG initiation therapy. There were no significant clinicopathological differences between the maintenance and no maintenance groups.

Table I.

Baseline characteristics of the maintenance and no maintenance groups.

Characteristics	Maintenance (n=92)	No maintenance (n=34)	P-value
Gender			0.273
Male	75	31
Female	17	3
Age (years)	61.73±11.865	65.88±11.762	0.083
T stage			0.086
Ta	25	15
T1	67	19
Carcinoma in situ			0.526
Yes	9	5
No	83	29
Grade			0.520
G1	14	6
G2	47	14
G3	28	14
Multiplicity			0.677
Single	33	11
Multiple	55	23
Recurrence history			0.793
Primary	75	27
Recurrent	15	7
Smoking history			0.178
Yes	29	23
No	25	10

The complications and side effects of immunotherapy are reported in Table II. The incidence of overall side effects was 40.2% in the maintenance group and 44.1% in the no maintenance group. Most of these complications were irritative symptoms (frequency, urgency and tenesmus). Two patients who had high-grade fever during maintenance therapy were treated with antipyretic medication. However, these patients had finished maintenance therapy. One patient who finished maintenance therapy had pulmonary tuberculosis.

Table II.

Toxicity and side effects of the maintenance and no maintenance groups.

Characteristics	Maintenance (n=92)	No maintenance (n=34)
Overall side effects	37 (40.2)	15 (44.1)
Local toxicity
Irritative symptom	30 (32.6)	14 (41.1)
Low-grade fever	1 (1.1)	0 (0.0)
Gross hematuria	5 (5.4)	2 (5.8)
Tuberculosis cystitis	2 (2.2)	0 (0.0)
Tuberculosis prostatitis	1 (1.1)	0 (0.0)
General toxicity
High-grade fever	2 (2.2)	0 (0.0)
Pulmonary tuberculosis	1 (1.1)	0 (0.0)

Fig. 1 shows RFS curves of the maintenance and no maintenance groups. The estimated median RFS was 87 months (95% CI 53.0–120.9) in the maintenance group and 48 months (95% CI 0–96.8) in the no maintenance group (log-rank test; P=0.002). The 2-year cumulative RFS rates were 77.3% in the maintenance group and 52.6% in the no maintenance group. The 5-year cumulative RFS rates were 64.4% in the maintenance group and 39.4% in the no maintenance group.

Figure 1.

Recurrence-free survival curves of the maintenance and no maintenance groups.

Fig. 2 shows PFS curves of the maintenance and no maintenance groups. Median PFS rates were not estimable in both groups (log-rank test; P=0.178). The 2-year cumulative PFS rates were 91.1% in the maintenance group and 80.5% in the no maintenance group. The 5-year cumulative PFS rates were 80.0% in the maintenance group and 71.6% in the no maintenance group.

Figure 2.

Progression-free survival curves of the maintenance and no maintenance groups.

Fig. 3 shows disease-specific survival (DSS) curves of the maintenance and no maintenance groups. Median DSS rates were not estimable in both groups (log-rank test; P=0.111). The 2-year cumulative DSS rates were 97.7% in the maintenance group and 91.4% in the no maintenance group. The 5-year cumulative DSS rates were 85.3% in the maintenance group and 74.3% in the no maintenance group.

Figure 3.

Disease-specific survival curves of the maintenance and no maintenance groups.

Discussion

Morales et al reported that adjuvant intravesical BCG therapy reduced tumor recurrence (3). Large randomized clinical trials performed by the SWOG demonstrated that BCG immunotherapy provides significantly longer time to first recurrence compared to chemotherapy. A randomized SWOG study reported that estimated median RFS was 76.8 months (95% CI 64.3–93.2) in the maintenance arm and 35.7 months (95% CI 25.1–56.8) in the no maintenance. They concluded that the overall 5-year survival was 83% in the maintenance arm compared to 78% in the no maintenance arm (4). Our study, using a monthly schedule, produced similar results: the estimated median RFS was 87 months (95% CI 53.0–120.9) in the maintenance group and 48 months (95% CI 0–96.8) in the no maintenance group. The 5-year survival rates were 85.3% in the maintenance group and 74.3% in the no maintenance group.

Two meta-analyses showed that intravesical BCG maintenance therapy reduced the risk of tumor progression (8,9). Sylvester et al reported that intravesical BCG significantly reduced the risk of tumor progression after transurethral resection in patients with superficial bladder cancer who received maintenance treatment. They identified 24 trials with progression information on 4,863 patients, and 260 of 2,658 patients in the BCG maintenance group (9.8%) had progression compared to 304 of 2,205 patients in the no maintenance group (13.8%) (8). Bohle et al revealed similar results for BCG prevention of tumor progression. They reported that BCG maintenance showed a statistically significant superiority over mitomycin C (OR=0.66; 95% CI 0.47–0.94) (9).

Several studies, however, have not been able to show that intravesical chemotherapy and immunotherapy have an influence on the time to progression to muscle invasive disease (4,16,17). Lamm et al found that maintenance chemotherapy failed to improve significant benefit of early post-operative intravesical chemotherapy. These data showed no decreased tumor progression, and overall among 2,011 randomized patients progression occurred in 7.5% of those receiving intravesical chemotherapy and 6.9% of those treated by surgery alone (17). Pawinski et al reported that no clear advantage of adjuvant treatment was shown with respect to progression to invasion, time to appearance of distant metastases or duration of survival and PFS. They concluded that, despite prolongation of the disease-free interval, adjuvant treatment has no apparent long-term impact on the evolution of stage Ta and T1 bladder cancer (16). The SWOG study reported that the estimated median time for worsening-free survival, defined as no evidence of progression, including pathological stage T2 disease or greater, or the use of cystectomy, systemic chemotherapy or radiation therapy, was 111.5 months in the no maintenance and not estimable in the maintenance arm (4).

Two monthly maintenance therapies for NMIBC have been reported (10,18). In a study by Badalament et al, 46 patients received BCG weekly for 6 weeks and were compared to 47 patients receiving the 6-weekly doses of BCG plus monthly BCG for 2 years. They concluded that patients receiving maintenance and no maintenance therapy had similar tumor recurrence and progression rates. These results indicate that monthly maintenance BCG does not prevent, delay or reduce tumor recurrence or progression observed with the 6-week regimen (10). In a study by Akaza et al, 39 patients receiving prophylactic maintenance therapy consisting of BCG of 40 mg monthly for 12 times were compared to 55 patients not receiving maintenance therapy. After a 3-year follow-up period, the final cumulative RFS rates were 77.6% in the maintenance group and 74.2% in the no maintenance group. They concluded that transurethral resection of tumors of the bladder alone is unlikely to eliminate the bladder tumor, and intravesical BCG is potentially the treatment of choice.

Our previous study examined changes in bladder mucosal immune cells in patients with superficial bladder carcinoma treated with BCG and doxorubicin. The post-treatment bladder mucosal B cells and T cells were significantly increased compared to pre-treatment in patients treated with BCG instillation. There was, however, no change in B or T cells in patients treated with doxorubicin. There was no tumor recurrence in cases with significantly increased numbers of B cells after BCG instillation. The results of our study suggest that intravesical BCG immunotherapy induces a significant increase in T cells as well as B cells, and B cells have a preventive effect on tumor recurrence. We conclude that stimulation at regular intervals may be effective to activate T and B cells, such as booster injection for immunization (19).

Regarding tumor progression, our results showed that the 2-year cumulative PFS rates were 91.1% in the maintenance group and 80.5% in the no maintenance group. However, the difference was not statistically significant. Maintenance therapy of the SWOG study consisted of intravesical and percutaneous BCG each week for 3 weeks, administered 3, 6, 12, 18, 24, 30 and 36 months from the initiation of induction therapy (4). The total number of maintenance therapy sessions was 21 in the SWOG study and 12 in our study. This difference may have affected the PFS rates. In addition, the difference in the number of patients between the maintenance and no maintenance groups and the small sample size reduced the statistical significance of the results. These were limitations of our case-control study.